Advertisement
Advertisement
BCRX
BioCryst Pharmaceuticals Inc
8.80
USDSponsored
+0.22
+2.56%
May 12, 15:59 UTC -4
Closed
Pre-Market
8.68
-0.12
-1.36%
BCRX Earnings Reports
Positive Surprise Ratio
BCRX beat 22 of 42 last estimates.
52%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$173.15M
/$0.06
Implied change from Q1 26 (Revenue/ EPS)
+10.70%
/-166.67%
Implied change from Q2 25 (Revenue/ EPS)
+5.99%
/+50.00%
BioCryst Pharmaceuticals Inc earnings per share and revenue
On May 06, 2026, BCRX reported earnings of -0.09 USD per share (EPS) for Q1 26, missing the estimate of 0.04 USD, resulting in a -281.82% surprise. Revenue reached 156.41 million, compared to an expected 154.15 million, with a 1.47% difference. The market reacted with a -2.21% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.06 USD, with revenue projected to reach 173.15 million USD, implying an decrease of -166.67% EPS, and increase of 10.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-53.85%
Relmada Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.19
Actual
-$0.22
Surprise
-10.61%
Perspective Therapeutics, Inc.
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.30
Actual
-$0.25
Surprise
+17.25%
Altimmune, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.24
Actual
-$0.18
Surprise
+27.18%
Prelude Therapeutics Incorporated
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.13
Surprise
+48.68%
Inhibikase Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.10
Surprise
+8.59%
Achieve Life Sciences, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.19
Surprise
+39.59%
Tonix Pharmaceuticals Holding Corp.
Report Date
May 11, 2026 For Q1 26
Estimate
-$2.48
Actual
-$2.93
Surprise
-18.05%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.38
Actual
-$0.41
Surprise
-5.92%
PolyPid Ltd. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.81%
FAQ
What were BioCryst Pharmaceuticals Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, BioCryst Pharmaceuticals Inc reported EPS of -$0.09, missing estimates by -281.82%, and revenue of $156.41M, 1.47% above expectations.
How did the market react to BioCryst Pharmaceuticals Inc's Q1 2026 earnings?
The stock price moved down -2.21%, changed from $9.03 before the earnings release to $8.83 the day after.
When is BioCryst Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for BioCryst Pharmaceuticals Inc's next earnings report?
Based on 6
analysts, BioCryst Pharmaceuticals Inc is expected to report EPS of $0.06 and revenue of $173.15M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement